Montelukast depression

Singulair Montelukast Asthma prophylaxis 3.0 10 Effexor Venlafaxine Anti-depressive 4 2.7... 

Psychiatric The US FDA has stated that post-marketing cases of neuropsychiatric events have been reported for montelukast and zafirlukast [105 ]. The events included agitation, aggression, anxiousness, dream abnormalities, hallucinations, depression,... 

A further review of three randomized controlled trials showed no evidence of a negative effect of montelukast on emotional wellbeing, using quality of life rather than indices of depression [107 ]. However, the studies that were included in these reviews were not originally designed to assess suicidahty or behavior-related adverse events. The authors also pointed out that sufferers of asthma and atopy have a higher than usual incidence of psychological morbidity, and that such reports are not unexpected. 

Holbrook JT, Harik-Khan R. Montelukast and emotional well-being as a marker for depression results from 3 randomized, double-masked clinical trials. J Allergy Clin Immunol 2008 122(4) 828-9. 

Neuropsychiatric Neuropsychiatric side-effects of montelukast have been discussed extensively previously [SEDA-35, 320]. A review of French, Swedish, Spanish, and North American pharmacovigilance registries included 851 psychiatric adverse effects [83 ]. The neuropsychiatric side-effects represented 20% of all adverse effects attributed to montelukast. The most frequently occurring neuropsychiatric side-effects among them were sleep disorders, behavioral disorders, depression, and suicidality, which included suicidal ideation, suicidal attempts, and suicides. 

---